Gastroparesis| A Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Jul 10, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat gastroparesis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180710005714/en/
Technavio has published a new report on the drug development pipeline for gastroparesis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Gastroparesis: Market overview
Gastroparesis is also known as delayed gastric emptying. It is a disorder, which results in slowing down or stopping food movement from stomach to small intestine due to improper or non-functioning of muscles in the stomach. This further results in delayed digestion. Complications of gastroparesis include dehydration, automatic loss of weight, malnutrition, and fluctuation in sugar level, which becomes hard to control.
According to a senior market research analyst at Technavio for research on infectious and rare diseases, “As per a research, in the US, around ten men and 40 women per 100,000 people have gastroparesis. Moreover, the symptoms that are found to be similar to gastroparesis occur in around one in four adults in the US.”
Gastroparesis: Segmentation analysis
This pipeline analysis report segments the gastroparesis market based on drug development strategies (gastroparesis, diabetic or idiopathic gastroparesis, and diabetic gastroparesis), therapies employed (monotherapy), MoA (5-HT4 agonist and 5 HT3 antagonist, dopamine receptor antagonist, nitric oxide donor, ghrelin receptor agonist, μ-opioid receptor antagonist, and neurokinin 1 receptor antagonist), geographical segmentation (EMEA, APAC, and Americas), and recruitment status (recruiting, completed, not yet recruiting, and enrolling by invitation). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005714/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/10/2018 10:59 AM/DISC: 07/10/2018 10:58 AM